Food supplement Rigvir SE is launched on the market

Company Smart Nanovirus Limited that has received a licence to develop the Rigvir virus in the non-medicine sector has successfully launched Rigvir SE on the market on 1st of July, 2023.
Rigvir Group wishes success and rapid expansion of the good virus around the world.

More Information

Oncolytic virus preclinical toxicology studies

Rigvir has once again received international confirmation that it is non-toxic, has high tolerability and does not induce any severe adverse event even at increased doses.

December 2022

Read More

Natural Intelligence Cancer Prevention Project

​Rigvir Group has signed a licence agreement with a UK-based company Smart Nanovirus Limited on a fundamentally new approach to cancer prevention, that would allow to identify high cancer risks timely and address them effectively, using the oncolytic virus Rigvir.

Read More

Shooting Star

To honour and thank Aina Muceniece – a scientist, oncologist, immunologist and virologist, as well as Rigvir inventor and founder of practical cancer virotherapy for the possibility to live a full life, Harijs Zariņš – a musician and poet, has composed a song called “Shooting Star”.

February 2022

Watch Video

“Another Taste of Life” film premiere on television

The movie tells us about 8 inspirational people affected by cancer gathering from all around the world to attempt the Mont Blanc. Movie is freely available in several languages on: www.anothertasteoflife.com

February 2022

Go to Website

A unique chronicle of Rigvir's development has been created on Instagram

January 2022

Read More

Rigvir group has signed a license agreement


Read More

Publication of New Toxicity study

January 2021

Read More

BIO Partnering at JP Morgan

November 2020

Read More

Rigvir Group finalised an ERAF funded project - GLP Toxicity Study of Rigvir

October 2020

Read More

Rigvir Group participates in BIO-Europe Digital

September 2020

Read More

GMP compliance certificate received

July 2020

Read More

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

June 2020

Read More

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy

May 2020

Read More

Rigvir Group concludes a deal with Chinese biotech company Sinorda Biomedicine

May 2020

Read More

Rigvir Group successfully attracted investments of EUR 500,000

The investment will be used in accordance with the Rigvir science program to strengthen the product's scientific capacity.

Read More

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

April 2020

Read More

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

April 2020

Read More

Attention, counterfeit!

March 2020

Read More

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

February 2020

Read More

A Case Report published: Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir

November 2019

Read More

Rigvir follow-up titre analyses completed

March 2019

Read More

Rigvir Group made a strategic decision temporarily suspend the distribution of Rigvir in Latvia

March 2019

Read More

Rigvir Group has sold International Virotherapy Center

December 2018

Read More

ESMO 2018 (Munich): The World’s Premier Congress in Medical Oncology

October 2018

Read More

Rigvir Group Assigns the Clinic to a New Partner

October 2018

Read More

The Regional Administrative Court Concludes: The Manufacturer of Rigvir has not Committed Unfair Commercial Practices

October 2018

Read More

The discussion on the pharmaceutical industry at The Public Health Subcommittee of the parliament of Republic of Latvia

October 2018

Read More

Presentation of scholarships by Vītols Fund and Rigvir Group

September 2018

Read More

IVC organizes international Melanoma Awareness Days

July 2018

Read More

Virotherapy combined treatment – new paradigm in cancer treatment

May 2018

Read More

Rigvir Group becomes a biotech company

May 2018

Read More

Oncolytic virotherapy approved in Uzbekistan

April 2018

Read More

The representative of the Group meets the Vice-President of the Chinese Business Confederation

January 2018

Read More

Rigvir Group company has recieved a €994,000 loan from EBRD and US private capital owned bank

December 2017

Read More

Rigvir Group receives LIAA funding for research in personalized medicine

December 2017

Read More

Vītols Foundation and Rigvir Group scholarships

September 2017

Read More

Rigvir Group receives “Seal of Exellence”

July 2017

Read More

WIPO Intellectual Property Award for Rigvir Group

April 2017

Read More

Rigvir Group team meets Ambassador of the UAE

April 2017

Read More

Rigvir Group delegation participating in the President Raimonds Vejonis working visit to the UAE

February 2017

Read More

Rigvir Group participates in diplomatic reception of Embassy of India

February 2017

Read More

Rigvir group participates in Arab Health 2017

January 2017

Read More

Rigvir Group congratulates everyone with Chinese New Year

January 2017

Read More

Discussion about oncolytic virotherapy in Latvian Academy of sciences

January 2017

Read More

Rigvir Group has donated 10 000 euros to Latvian Cancer Patient Support Society "Dzivibas koks"

December 2016

Read More

Rigvir Group takes part in Central and Eastern Europe countries and China summit

November 2016

Read More

Participation in 24th World Cancer Congress 2016

November 2016

Read More

Signing of cooperation agreement between the Latvian and Chinese Academies of Sciences

November 2016

Read More

Export and Innovation Award 2016

October 2016

Read More

SME Instrument Innovators’ Summit 2016

October 2016

Read More

Melanoma screening campaign calls for preventive skin check-ups

September 2016

Read More

Ministry of Economics of the Republic of Latvia honours the Rigvir Group for awarding the grant from European Commission in order to initiate the commercialization in the EU markets

August 2016

Read More

Horizon 2020 grant for cancer virotherapy medicine

July 2016

Read More

Vitols family invests in established cancer virotherapy excellence center

June 2016

Read More

Oncolytic virotherapy approved in Armenia

May 2016

Read More

Visit of Ambassador of Sweden

May 2016

Read More

Opening of the Global Virotherapy Cancer Clinic

February 2016

Read More

Aina Muceniece Virotherapy Foundation established

February 2016

Read More

Rigvir Group announces a grant programme

January 2016

Read More

Agreement between Rigvir Group and charity foundation “Vītolu fonds”

January 2016

Read More

IV Virotherapy conference

November 2015

Read More

New clinical guidelines recommends oncolytic virotherapy

August 2015

Read More

Oncolytic virotherapy approved in Georgia

May 2015

Read More

Meeting with Sheikh Taleb bin Saqr Al Qassimi

January 2015

Read More

Visit to the United Arab Emirates and a meeting with the Minister of Health (UAE) - Abdul Rahman Mohammed Al Owaisbr

January 2014

Read More

Oncolytic virotherapy with RIGVIR® is reimbursable medication

2011

Read More

Opening of the International Viroterapy Center (IVC)

2008

Read More

State Agency of Medicines of the Republic of Latvia registers RIGVIR®

2004

Read More